A new selective androgen receptor modulator (SARM) called MK4541 is starting to make a name for itself in the pharmaceutical world for its ability to help improve the quality of life among men with prostate cancer.
Let’s give this compound a closer look…
The Rundown on MK4541
At its simplest, MK4541 is designed to get rid of androgen-independent prostate cancer cells by inducing their death in men suffering from the disease.
Now while there are already a number of treatments and preventive options for the enlargement of the prostate and prostate cancer available these days, they tend to mess up the body’s ideal androgen levels in the long run.
This disruption leads to a number of adverse behavioral and musculoskeletal side effects like sexual dysfunction, osteoporosis, and bone fractures as well as mood swings sooner or later.
What makes MK4541 different from these treatments is it has the ability to induce apoptosis or programmed cell death in prostate cancer cells without causing the body to get into an androgen-deficient condition. This means that this SARM could help get rid of prostate cancer without causing the adverse side effects promoted by traditional treatments available nowadays.
This compound is still currently being assessed in a battery of clinical trials to see its full efficacy.
Surprising Added Benefits
What’s really interesting about MK4541 is it set off some rather surprising additional benefits when administered to male rats.
Besides being seen to stave off androgen-dependent prostate growth, this SARM also helped maintain ideal bone density and lean body mass in the process. Experts even imagine that MK4541 may hold more anabolic benefits and should be studied further.
We will update this post as soon as we can when there are new developments on MK4541. In the meantime, you can also check out other SARMS right here.